Imagion Biosystems Limited (IBL), an Australian medical device company, is developing a new non-invasive cancer detection technology. Unlike existing medical imaging technologies that identify a “region of interest” IBL’s MagSense™ technology has the potential to provide non-invasive, molecularly specific, detection of cancerous tumors. It will be the first new form of medical imaging in more than 50 years. The diagnostic imaging technology is based on the principles of Superparamagnetic Relaxometry (SPMR) and includes a detection instrument system and a injectable tracer which is a cancer-specific nanoparticle test reagent. The test reagent is administered to the patent before measurement, e.g. via intravenous or subcutaneous injection, and the bio-functionalized nanoparticles target and bind to the cancer cells and are detectable by the instrument. The technology is not restricted to diagnosis or detection of one kind of cancer but is broadly applicable for detecting a many solid tumors and will be more sensitive than current imaging technologies.,Imagion Biosystems Limited (IBL), an Australian medical device company, is developing a new non-invasive cancer detection technology. Unlike existing medical imaging technologies that identify a “region of interest” IBL’s MagSense™ technology has the potential to provide non-invasive, molecularly specific, detection of cancerous tumors. It will be the first new form of medical imaging in more than 50 years. The diagnostic imaging technology is based on the principles of Superparamagnetic Relaxometry (SPMR) and includes a detection instrument system and a injectable tracer which is a cancer-specific nanoparticle test reagent. The test reagent is administered to the patent before measurement, e.g. via intravenous or subcutaneous injection, and the bio-functionalized nanoparticles target and bind to the cancer cells and are detectable by the instrument. The technology is not restricted to diagnosis or detection of one kind of cancer but is broadly applicable for detecting a many solid tumors and will be more sensitive than current imaging technologies.

Arcis have developed and launched a CE-IVD approved ultra-rapid DNA & RNA extraction and preservation technology. In under 3 minutes the technology extracts DNA & RNA from virtually any sample and preserves it instantly for downstream amplification and disease detection. RNA in particular is very fragile and degrades quickly but once preserved in the Arcis reagents it is stable for over 30 days at room temperature - allowing much more accurate detection of a disease or pathogen or even of a cancer biomarker. Arcis have shown that fragile cancer biomarkers can be preserved by using the Arcis technology in urine ( a very difficult bodily fluid). In conjunction with a leading UK University and a Prostate Cancer Charity, results have been demonstrated at detecting RNA cancer biomarkers in urine for up to 7 days (usually they instantly degrade and thus cannot be detected). The plan is to continue developing and then launching (in 2021) a home screening prostate cancer test whereby the consumer simply urinates into a pot containing Arcis, and if any fragile cancer biomarkers are present then they are instantly preserved. The consumer send the pot in the post and a screening assay is then performed to detect the preserved biomarkers. This is far more effective than the current PSA blood test, which can be inaccurate. The other area we are seeing great interest - specifically in China - is in rapid pathogen detection in food , plants, soil, animals and also of course in humans (infectious diseases etc). The Arcis Technology is low cost, rapid (under 3 minutes) and requires no special training or lab equipment. So it can be deployed out of the lab and in "point of care" settings. Chinese government ministries and large pathogen testing labs are currently validating the Arcis Technology in their workflows.,Arcis have developed and launched a CE-IVD approved ultra-rapid DNA & RNA extraction and preservation technology. In under 3 minutes the technology extracts DNA & RNA from virtually any sample and preserves it instantly for downstream amplification and disease detection. RNA in particular is very fragile and degrades quickly but once preserved in the Arcis reagents it is stable for over 30 days at room temperature - allowing much more accurate detection of a disease or pathogen or even of a cancer biomarker. Arcis have shown that fragile cancer biomarkers can be preserved by using the Arcis technology in urine ( a very difficult bodily fluid). In conjunction with a leading UK University and a Prostate Cancer Charity, results have been demonstrated at detecting RNA cancer biomarkers in urine for up to 7 days (usually they instantly degrade and thus cannot be detected). The plan is to continue developing and then launching (in 2021) a home screening prostate cancer test whereby the consumer simply urinates into a pot containing Arcis, and if any fragile cancer biomarkers are present then they are instantly preserved. The consumer send the pot in the post and a screening assay is then performed to detect the preserved biomarkers. This is far more effective than the current PSA blood test, which can be inaccurate. The other area we are seeing great interest - specifically in China - is in rapid pathogen detection in food , plants, soil, animals and also of course in humans (infectious diseases etc). The Arcis Technology is low cost, rapid (under 3 minutes) and requires no special training or lab equipment. So it can be deployed out of the lab and in "point of care" settings. Chinese government ministries and large pathogen testing labs are currently validating the Arcis Technology in their workflows.

旨在调查快递小哥的工作强度等问题，了解他们的心理状况及相关因素并呈现给社会，进而提高整个社会对这一群体的认知水平，呼吁社会给快递小哥多一份理解和关爱，完善职业保障，优化行业管理。,旨在调查快递小哥的工作强度等问题，了解他们的心理状况及相关因素并呈现给社会，进而提高整个社会对这一群体的认知水平，呼吁社会给快递小哥多一份理解和关爱，完善职业保障，优化行业管理。

EYE TECH CARE is a French ophthalmology company backed by private European and Chinese investors, founded in 2008. The company has developed EyeOP1?, a unique non-invasive medical device to treat glaucoma with ultrasound, based on a proprietary technology. Glaucoma is a chronic serious disease that affects over 90 million people worldwide, growing constantly due to aging population. The standard of care are eyedrops which often lose their therapeutic effect over time and surgery which in turn is related to significant risks of complications. EyeOP1? went through the clinical phase and has CE mark approval. Over 8,000 patients have been treated and over 100 clinical papers and abstracts were published. EYE TECH CARE has a dedicated commercial strategy for China with its 25 million glaucoma patients and where access and infrastructure for sophisticated glaucoma surgery is limited and patients present often with advanced disease stages. The company got registration from the Chinese FDA in October 2017 giving a significant competitive advantage as no other innovative product for glaucoma is approved in this market and EYE TECH CARE will have an estimated advance of 3 to 4 years. The company created a wholly owned subsidiary in Shanghai and built a commercial and clinical team with revenues entering since Q1/2018. Regional sales channels were set-up with distributors carefully selected and constantly on the spot for their performance. Thus, the team achieved in its first year of commercialization in China a broad success both in numbers and in brand awareness. Over 100 centers in China already treated over 1000 patients within product demonstrations, several EyeOP1 systems were commercially sold and the sales pipeline comprises over 130 top tear level hospitals. The majority of distributors that had been assigned to a total of 10 territories kept their commitments and the company set the course to continue strong growth and market penetration. While the company is focusing on growth in China, additional emerging markets are being addressed and the product is already approved in the Middle East, India, some South East Asian countries, and Mexico. The company is opening a new fund raising round to back-up growth in China and bridge the period until break-even in 2021/2022.,EYE TECH CARE is a French ophthalmology company backed by private European and Chinese investors, founded in 2008. The company has developed EyeOP1?, a unique non-invasive medical device to treat glaucoma with ultrasound, based on a proprietary technology. Glaucoma is a chronic serious disease that affects over 90 million people worldwide, growing constantly due to aging population. The standard of care are eyedrops which often lose their therapeutic effect over time and surgery which in turn is related to significant risks of complications. EyeOP1? went through the clinical phase and has CE mark approval. Over 8,000 patients have been treated and over 100 clinical papers and abstracts were published. EYE TECH CARE has a dedicated commercial strategy for China with its 25 million glaucoma patients and where access and infrastructure for sophisticated glaucoma surgery is limited and patients present often with advanced disease stages. The company got registration from the Chinese FDA in October 2017 giving a significant competitive advantage as no other innovative product for glaucoma is approved in this market and EYE TECH CARE will have an estimated advance of 3 to 4 years. The company created a wholly owned subsidiary in Shanghai and built a commercial and clinical team with revenues entering since Q1/2018. Regional sales channels were set-up with distributors carefully selected and constantly on the spot for their performance. Thus, the team achieved in its first year of commercialization in China a broad success both in numbers and in brand awareness. Over 100 centers in China already treated over 1000 patients within product demonstrations, several EyeOP1 systems were commercially sold and the sales pipeline comprises over 130 top tear level hospitals. The majority of distributors that had been assigned to a total of 10 territories kept their commitments and the company set the course to continue strong growth and market penetration. While the company is focusing on growth in China, additional emerging markets are being addressed and the product is already approved in the Middle East, India, some South East Asian countries, and Mexico. The company is opening a new fund raising round to back-up growth in China and bridge the period until break-even in 2021/2022.

本项目以物联网云平台为载体，利用人工智能、微流控，非线性数值模拟等先进技术对水厂的爆气、加药及消毒等关键工艺环节进行精细化控制，取代传统落后产能。随着人工成本及材料成本的增加、环保部门要求日益严格，目前水厂对提标改造的需求非常迫切。目前中国市场上本项目技术处于起步阶段，针对的用户包括旧水厂的提标改造及新建水厂的自动化控制，因此具有广阔的发展空间。本创业团队人才汇聚，知识面广、业务能力强，对于消毒设备的智能制备及精确投加、智能加药等技术具有多年的研究经验，目前已成功完成某国有集团2个提标改造项目。,本项目以物联网云平台为载体，利用人工智能、微流控，非线性数值模拟等先进技术对水厂的爆气、加药及消毒等关键工艺环节进行精细化控制，取代传统落后产能。随着人工成本及材料成本的增加、环保部门要求日益严格，目前水厂对提标改造的需求非常迫切。目前中国市场上本项目技术处于起步阶段，针对的用户包括旧水厂的提标改造及新建水厂的自动化控制，因此具有广阔的发展空间。本创业团队人才汇聚，知识面广、业务能力强，对于消毒设备的智能制备及精确投加、智能加药等技术具有多年的研究经验，目前已成功完成某国有集团2个提标改造项目。

构建一个预测模型，对脑血管意外进行较为准确的预测，并对处于高风险的患者进行更为严格的干预，降低这部分患者的脑血管意外事件发生率,构建一个预测模型，对脑血管意外进行较为准确的预测，并对处于高风险的患者进行更为严格的干预，降低这部分患者的脑血管意外事件发生率